Global Life Science Business Partnering (GLSBP) - December 2024

Highlights of Deals in December 2024

 

We Wish You a Very Happy New Year 2025

 

1.     Akums Group, India’s largest CDMO, has entered a 200 Million Euro (Rs 1,760 crore) partnership with a global pharmaceutical major to manufacture and supply a range of pharmaceutical formulations for the European market.

2.     Quadria Capital is set to acquire a 10% stake in India based Aragen Life Sciences for about US$100 million at a valuation of US$1.2 Billion.

3.     Sun Pharma Advanced Research Company (SPARC) acquires 55% equity stake in Tiller Therapeutics.

4.     Lupin acquires 'Huminsulin' in India from Eli Lilly and Co.

5.     India-based Mankind Pharma has entered a partnership with Innovent Biologics for exclusively licensing and commercializing of sintilimab, an immunotherapy for cancer treatment in India.

6.     Valneva has entered into an exclusive license agreement for its single-shot chikungunya vaccine that enables supply of the vaccine in Asia with Serum Institute of India (SII).

7.     Suven Pharmaceuticals to acquire controlling stake in US-based company NJ Bio.

8.     BioAge Labs inks US$500 Million+ collaboration with Novartis.

9.     Novavax to sell Czech manufacturing unit to Novo Nordisk for US$200 Million.

10.  AbbVie to acquire Nimble Therapeutics for US$200 Million.

11.  Astellas partners with Sangamo on cutting-edge gene therapy, paying $20 million right away and up to $1.3 billion in milestones.

12.  Certa Therapeutics, a biotech developing precision therapies for fibrotic diseases, has acquired fellow Australian firm OccuRx.

13.  Kaken Pharmaceutical has entered into a license agreement with US healthcare giant Johnson & Johnson for the global development, manufacturing and commercialization of a STAT6 program that Kaken is developing.

 

Aagami Updates:

1.     New Client Win - Sale of IP Portfolio of First-in-Class Non-Opioid Analgesic in clinical stage.

2.     Aagami completed 22 years in business.

3.     Aagami CEO to attend JPM week 2025 and Biotech Showcase in San Francisco from January 13-16, 2025. Calendar filling fast. Limited options still open, please send us your meeting requests soon.

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses. Also, Phase 2 trials are starting in Central Africa for MPOX.

2.     Licensing: Several Biosimilars available for Partnering in Japan

a.     Denosumab (Prolia® & Xgeva®)

b.     Romiplostim (Nplate®) [ For immune thrombocytopenia (ITP) ]

c.     Teriparatide (Forteo®/Forsteo®) [ For Osteoporosis ]  

3.     Seeking Acquisition /JV – Clinical stage Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia [Second Human Trial (n=30) ongoing in AU].

  1. Seeking Partnering: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – For 1) Depression and ALS 2) Anti-Obesity.

For Acquisition:

1.    Lucrative Opportunity to acquire IP Portfolio of First-in-Class Non-Opioid Analgesic.

2.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

3.     US IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).

4.     Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

  1. Seeking Investment: Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications.
  2. Seeking Investments/Partnerships: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – 1. For Depression and ALS 2. Anti-Obesity.
  3. Engineering Therapeutics to Block Pathogenic Autoantibodies: Currently Need $4M seed to:
    1. Define clear FDA regulatory path
    2. Complete formulation of lead decoy; GLP studies in vitro
    3. Prepare for $7-$10M Series A raise for First in Human trials

Specialized Services

1.     Oligonucleotide and peptides specialist Japanese CDMO for one stop solution to accelerate R&D.

2.     In vivo pharmacology specialists (Mirimus) - Your new partner in Drug Discovery.

Hope you found the content useful. We welcome your feedback and queries.

×
Twitter